iShares MSCI Taiwan ETF vs Revolution Medicines Inc. Common Stock — how do they compare? iShares MSCI Taiwan ETF trades at $114.37 (market cap $12.74B), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 3.2× iShares MSCI Taiwan ETF's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Revolution Medicines Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| EWT | RVMD | |
|---|---|---|
Market Cap | $12.74B | $40.32B |
Volume | 8,470,920 | 4,855,734 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $221.15 |
52-Week Low | $60.03 | $47.50 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $37.02B |
Signals from Pluang's Aura AI — not financial advice
EWT trades at $114.31, down 1.66% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong exposure to Taiwan's semiconductor sector, particularly TSMC, driving AI-related growth potential. Recent news highlights Taiwan's $20 billion investment in US AI infrastructure and institutional buying interest from Bank of America.
Outlook remains positive due to Taiwan's central role in AI chip manufacturing, though geopolitical risks with China pose significant headwinds. Valuation appears reasonable for tech-focused exposure, but investors must weigh growth potential against regional political uncertainty.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →